Samrat Pharma

{
  "main_header": {
    "sid": 116063,
    "name": "Samrat Pharma",
    "stock_name": "Samrat Pharma",
    "full_name": "Samrat Pharmachem Ltd",
    "name_url": "stocks-analysis/samrat-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "192.60",
    "chg": -3.05,
    "chgp": "-1.56%",
    "dir": -1,
    "prev_price": "195.65",
    "mcapval": "60.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530125,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE103E01016",
    "curr_date": "Mar 30",
    "curr_time": "",
    "bse_nse_vol": "6.71 k",
    "exc_status": "Active",
    "traded_date": "Mar 30, 2026",
    "traded_date_str": "2026 03 30",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/samrat-pharma-116063-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Samrat Pharmachem Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharmachem-ltd-is-rated-strong-sell-3923788",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SamratPharmache_mojoScore_3923788.png",
        "date": "2026-03-30 10:10:17",
        "description": "Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 30 March 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Five Consecutive Losses Push Samrat Pharmachem Ltd to a New 52-Week Low",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-ltd-stock-hits-52-week-low-at-rs1944-3924033",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SamratPharmache_priceRelatedfactors_3924033.png",
        "date": "2026-03-30 09:53:39",
        "description": "For the fifth consecutive session, Samrat Pharmachem Ltd closed lower, hitting a fresh 52-week low of Rs 194.4 on 30 Mar 2026. This decline comes amid a broader market that has shown some resilience, underscoring the stock's persistent underperformance."
      },
      {
        "title": "Why is Samrat Pharmachem Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-samrat-pharmachem-ltd-fallingrising-3921083",
        "imagepath": "",
        "date": "2026-03-28 01:24:34",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Intraday Price Movements and Trading Dynamics</strong></p>\n<p>Despite opening the day with a positive gap of 3.63%, reaching an intraday high of ₹212.50, the stock reversed sharply to close near its lowest point of the day. The weighted average price indicates that a larger volume of shares traded closer to the day’s low, signalling selling pressure as the session progressed. This intraday volatility suggests that initial optimism was quickly overshadowed by bearish sentiment among investors.</p>\n<p><strong>Technical Indicators Point to Downtrend</strong></p>\n<p>Samrat Pharmachem is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment of moving averages below the stock price is a classic technical indicator of sus..."
      },
      {
        "title": "Samrat Pharmachem Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharmachem-ltd-is-rated-strong-sell-3893267",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SamratPharmache_mojoScore_3893267.png",
        "date": "2026-03-16 10:10:15",
        "description": "Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 March 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Samrat Pharmachem Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharmachem-ltd-is-rated-strong-sell-3873120",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SamratPharmache_mojoScore_3873120.png",
        "date": "2026-03-05 10:10:20",
        "description": "Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Samrat Pharmachem Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharmachem-ltd-is-rated-strong-sell-3850643",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SamratPharmache_mojoScore_3850643.png",
        "date": "2026-02-22 10:10:29",
        "description": "Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Samrat Pharmachem Ltd Faces Sharp Valuation Reassessment Amid Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-ltd-faces-sharp-valuation-reassessment-amid-market-pressure-3843094",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SamratPharmache_valuationdot_3843094.png",
        "date": "2026-02-17 08:00:10",
        "description": "Samrat Pharmachem Ltd has witnessed a significant shift in its valuation parameters, with key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios deteriorating sharply compared to historical averages and peer benchmarks. This change has coincided with a steep decline in the stock price, prompting a downgrade in its investment grade to Strong Sell by MarketsMOJO as of 19 Aug 2025."
      },
      {
        "title": "Samrat Pharmachem Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharmachem-ltd-is-rated-strong-sell-3830447",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SamratPharmache_mojoScore_3830447.png",
        "date": "2026-02-10 10:10:48",
        "description": "Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 February 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Samrat Pharmachem Ltd Valuation Shifts Signal Elevated Price Risk Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-ltd-valuation-shifts-signal-elevated-price-risk-amid-sector-challenges-3815211",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SamratPharmache_valuationdot_3815211.png",
        "date": "2026-02-02 08:00:15",
        "description": "Samrat Pharmachem Ltd’s valuation metrics have recently deteriorated, shifting from expensive to very expensive territory, raising concerns about its price attractiveness amid a challenging sector backdrop and subdued returns relative to benchmarks."
      }
    ],
    "total": 5746,
    "sid": "116063",
    "stock_news_url": "https://www.marketsmojo.com/news/samrat-pharmachem-116063"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "25-Mar-2026",
      "details": "Closure of Trading Window from 01-04-2026 till 48 hours after the declaration of Audited Financial Results for the year ended 31/03/2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Audited Financial Results For The Financial Year Ended March 31 2026",
      "datetime": "25-Mar-2026",
      "details": "Samrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve the Audited Financial Results for the year ended March 31 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "18-Feb-2026",
      "details": "Newspaper Publication - Extract of Un-audited financial results for the quarter ended 31 December 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "30 May 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Samrat Pharmachem Ltd has declared <strong>10%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Samrat Pharmachem Ltd is Rated Strong Sell

2026-03-30 10:10:17

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 30 March 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Five Consecutive Losses Push Samrat Pharmachem Ltd to a New 52-Week Low

2026-03-30 09:53:39

For the fifth consecutive session, Samrat Pharmachem Ltd closed lower, hitting a fresh 52-week low of Rs 194.4 on 30 Mar 2026. This decline comes amid a broader market that has shown some resilience, underscoring the stock's persistent underperformance.

Read full news article

Why is Samrat Pharmachem Ltd falling/rising?

2026-03-28 01:24:34

Intraday Price Movements and Trading Dynamics

Despite opening the day with a positive gap of 3.63%, reaching an intraday high of ₹212.50, the stock reversed sharply to close near its lowest point of the day. The weighted average price indicates that a larger volume of shares traded closer to the day’s low, signalling selling pressure as the session progressed. This intraday volatility suggests that initial optimism was quickly overshadowed by bearish sentiment among investors.

Technical Indicators Point to Downtrend

Samrat Pharmachem is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment of moving averages below the stock price is a classic technical indicator of sus...

Read full news article

Samrat Pharmachem Ltd is Rated Strong Sell

2026-03-16 10:10:15

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 March 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Samrat Pharmachem Ltd is Rated Strong Sell

2026-03-05 10:10:20

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Samrat Pharmachem Ltd is Rated Strong Sell

2026-02-22 10:10:29

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Samrat Pharmachem Ltd Faces Sharp Valuation Reassessment Amid Market Pressure

2026-02-17 08:00:10

Samrat Pharmachem Ltd has witnessed a significant shift in its valuation parameters, with key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios deteriorating sharply compared to historical averages and peer benchmarks. This change has coincided with a steep decline in the stock price, prompting a downgrade in its investment grade to Strong Sell by MarketsMOJO as of 19 Aug 2025.

Read full news article

Samrat Pharmachem Ltd is Rated Strong Sell

2026-02-10 10:10:48

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 February 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Samrat Pharmachem Ltd Valuation Shifts Signal Elevated Price Risk Amid Sector Challenges

2026-02-02 08:00:15

Samrat Pharmachem Ltd’s valuation metrics have recently deteriorated, shifting from expensive to very expensive territory, raising concerns about its price attractiveness amid a challenging sector backdrop and subdued returns relative to benchmarks.

Read full news article

View All News